2-(3-methoxy-phenyl)-propionyl chloride | 176693-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(3-methoxy-phenyl)-propionyl chloride
• 英文别名: 2-(3-methoxyphenyl)propanoyl chloride；3-methoxyphenylpropionylchloride
• CAS: 176693-88-2
• 化学式: C₁₀H₁₁ClO₂
• 分子量: 198.649
• InChiKey: SOGRRYNEYYTISX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-methoxy-phenyl)-propionyl chloride 在 sodium hydroxide 、 乙酸酐 、 三乙胺 作用下， 反应 0.5h， 生成 3-[2-[1-(3-methoxyphenyl)ethyl]-5-oxo-4-propan-2-yl-1,3-oxazol-2-yl]propanenitrile
  参考文献：
  名称：

  McKay, Roslyn; Proctor, George R., Journal of Chemical Research - Part S, 1996, # 2, p. 98 - 99

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(3-甲氧基苯基)丙酸乙酯 在 sodium hydroxide 、 氯化亚砜 作用下， 生成 2-(3-methoxy-phenyl)-propionyl chloride
  参考文献：
  名称：

  McKay, Roslyn; Proctor, George R., Journal of Chemical Research - Part S, 1996, # 2, p. 98 - 99

  摘要：

  DOI：

文献信息

• BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL
  申请人：Kuo Gee-Hong

  公开号：US20070244094A1

  公开（公告）日：2007-10-18

  The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

  该发明涉及一种化合物，其化学式为（I），可用作PPAR激动剂。还描述了使用该发明的化合物治疗糖尿病、肾病、神经病、视网膜病变、多囊卵巢综合征、高血压、缺血、中风、肠易激综合征、炎症、白内障、心血管疾病、代谢X综合征、高LDL胆固醇血症、血脂异常（包括高甘油三酯血症、高胆固醇血症、混合性高脂血症和低HDL胆固醇血症）、动脉粥样硬化、肥胖以及其他与脂质代谢和能量稳态并发症相关的疾病的药物组合物和治疗方法。
• Total Synthesis of (±)-Lennoxamine and (±)-Aphanorphine by Intramolecular Electrophilic Aromatic Substitution Reactions of 2-Amidoacroleins
  作者：James R. Fuchs、Raymond L. Funk

  DOI：10.1021/ol016795b

  日期：2001.11.1

  Intramolecular electrophilic aromatic substitution reactions of 2-amidoacroleins constitute the key steps in the total syntheses of lennoxamine and aphanorphine. The aldehyde moiety of one cyclization product was transformed to a double bond, which was then engaged in a radical cyclization to produce the complete ring system of lennoxamine. The aldehyde functionality of the other cyclization product

  2-酰胺基丙烯醛的分子内亲电芳族取代反应构成了伦诺沙明和甲啡肽的总合成中的关键步骤。将一种环化产物的醛部分转化为双键，然后将其进行自由基环化，以生成lennoxamine的完整环系。将另一种环化产物的醛官能团转化为相应的甲磺酸酯，其通过内酰胺烯醇酯进行分子内置换，以提供甲啡肽的环系统。[反应：看文字]
• Compounds and methods for modulation of estrogen receptors
  申请人：Signal Pharmaceuticals, Inc.

  公开号：US20040082575A1

  公开（公告）日：2004-04-29

  Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-&bgr;. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

  本发明揭示了调节雌激素受体（ER）的化合物，以及包含这些化合物的药物组合物。在一个具体的实施例中，这些化合物对ER-β比ER-α具有选择性。揭示了在表达具有偏好ER-β的细胞和/或组织中调节ER-β的方法，包括治疗雌激素相关疾病的方法，例如乳腺癌、睾丸癌、骨质疏松症、子宫内膜异位症、心血管疾病、高胆固醇血症、前列腺增生、前列腺癌、肥胖、潮热、皮肤影响、情绪波动、记忆力下降、尿失禁、脱发、白内障、自然激素失衡以及与环境化学物质暴露相关的不良生殖影响。
• Catalytic Desymmetrizing Baeyer–Villiger Oxidation of Quaternary Carbon-Containing Cyclobutane-1,3-diones
  作者：Chao Liu、Feng-Lan Zou、Kai-Ge Wen、Yi-Yuan Peng、Qiu-Ping Ding、Xing-Ping Zeng

  DOI：10.1021/acs.orglett.3c01852

  日期：2023.8.11

  carbon-containing cyclobutane-1,3-diones using chiral phosphoric acid catalysis and commercially available oxidants was reported. According to the structure of the substrates, two optimized reaction conditions were developed to afford the corresponding chiral tetronic acid products in ≤93% and ≤95% ee values. This reaction offers the first catalytic asymmetric approach to chiral 5,5-disubstituted tetronic acid derivatives

  首次报道了使用手性磷酸催化和市售氧化剂对含季碳环丁烷-1,3-二酮进行高度对映选择性拜耳-维利格氧化。根据底物的结构，开发了两种优化的反应条件，得到了相应的手性季酮酸产物，其ee值≤93%和≤95%。该反应为手性 5,5-二取代特窗酸衍生物提供了第一个催化不对称方法。(−)-vertinolide 的正式不对称合成和 plakinidone B 的首次催化不对称全合成证明了该方法的合成潜力。
• Remote Construction of N‐Heterocycles via 1,4‐Palladium Shift‐Mediated Double C−H Activation
  作者：Takeru Miyakoshi、Nadja E. Niggli、Olivier Baudoin

  DOI：10.1002/anie.202116101

  日期：2022.4.19

  AbstractIn the past years, Pd0‐catalyzed C(sp3)−H activation provided efficient and step‐economical methods to synthesize carbo‐ and heterocycles via direct C(sp2)−C(sp3) bond formation. We report herein that a 1,4‐Pd shift allows access to N‐heterocycles which are difficult to build via a direct reaction. It is shown thato‐bromo‐N‐methylanilines undergo a 1,4‐Pd shift at theN‐methyl group, followed by intramolecular trapping by C(sp2)−H or C(sp3)−H activation at another nitrogen substituent and remote C−C bond formation to generate biologically relevant isoindolines and β‐lactams. The product selectivity is influenced by the employed ligand, with NHCs favoring the product of remote C−C coupling against products arising from direct C−C coupling and N‐demethylation.